United Therapeutics Corporation of Canada
GPTKB entity
Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Company
|
| gptkbp:acquisition |
Steady Med Therapeutics
|
| gptkbp:ceo |
gptkb:Martine_Rothblatt
|
| gptkbp:employees |
over 500
|
| gptkbp:focus |
developing and commercializing unique products to address the unmet needs of patients with chronic and life-threatening conditions
|
| gptkbp:founded |
gptkb:1996
|
| gptkbp:headquarters |
Silver Spring, Maryland, USA
|
| https://www.w3.org/2000/01/rdf-schema#label |
United Therapeutics Corporation of Canada
|
| gptkbp:partnership |
gptkb:Boehringer_Ingelheim
gptkb:Pfizer |
| gptkbp:products |
gptkb:Orenitram
gptkb:Remodulin gptkb:Tyvaso gptkb:Unituxin |
| gptkbp:research_focus |
organ transplantation
cancer therapies pulmonary arterial hypertension |
| gptkbp:traded_on |
gptkb:NASDAQ
|
| gptkbp:website |
www.unither.com
|
| gptkbp:bfsParent |
gptkb:United_Therapeutics_Corporation
|
| gptkbp:bfsLayer |
6
|